David Rodenhiser
Affiliations
Scientist, Division of Genetics & Development, Children’s Health Research Institute
Associate Professor, Department of Paediatrics, Biochemistry and Oncology, Schulich School of Medicine & Dentistry, Western University
Principal Investigator, London Regional Cancer Program
How my research helps children
My research focuses on ‘epigenetics’: a process in which genes are turned on (or off) without a direct change in the DNA sequence. This epigenetic regulation of gene expression is critically important during embryonic development and in tumour formation. Epigenetic errors in DNA methylation patterns and histone modifications can alter gene expression, cause aberrant developmental programs and lead to many paediatric and adult cancers. I am particularly interested in how epigenetic mechanisms mediate environmental effects on development.
Research
Current Research Activities
Ongoing research in my lab focuses on (a) defining the functional important of DNA methylation changes in tumour formation in general and cancer metastasis in particular, (b) determining how cancer-causing compounds in the environment alter epigenetic patterns and contribute to tumour formation and (c) defining how these environmental pollutants alter epigenetic patterns and compromise embryonic development.
Research Team
At present my lab consists of a technician and bioinformatics specialist (Joe Andrews) and I co-supervise a PhD student (Kay Skrowonski) along with Dr Brenda Coomber at the University of Guelph. A number of former trainees from my lab have gone on to medical school, as well as to further graduate work at academic institutions in Canada and the US (Princeton, Baylor and Toronto), and into industry (Myriad Genetics).
Future Research Plans
I have a long-term interest in understanding how cells respond at the molecular level to environmental stress. Epigenetic processes are critically important to these responses and when these processes are impaired, embryonic development can be altered (leading to paediatric disorders) or cells can become uncontrollable (tumours can develop). My research program has multiple foci, including studying epigenetic changes due to chemical exposure during Xenopus development (with Dr. Tom Drysdale) the evolutionary impact of epigenetic processes in cancer metastasis (with Dr. Ann Chambers), looking at epigenetic regulation of new blood vessels in response to hypoglycemia and hypoxia (with Dr. Brenda Coomber) and on the contribution of epigenetic factors in pancreatitis (with Drs. Chris Pin and Rashid Mehmood).
Awards & Grants
Awards & Grants
Ongoing funding in support of: Initiative in Environmental Epigenetics using Xenopus – Awarded by Western University (ADF)
Ongoing funding in support of: The role of ischemia in tumor progression: implications for response to therapy – Awarded by Canadian Cancer Society Research Institute (CCSRI)
Previous funding in support of Steps in Breast Cancer metastasis: Cell and animal models of lymphatic metastasis and post-surgical therapy of breast cancer and Modelling of critical steps in mammary tumour progression in 3D culture and in vivo – Awarded by Canadian Breast Cancer Research Alliance
Recent Publications
Selected Publications
Gene signatures of breast cancer progression and metastasis. Rodenhiser DI, Andrews JD, Vandenberg TA, Chambers AF (2011). Breast Cancer Research 13: 201-8.
Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. Andrews J, Kennette W, Pilon JM, Hodgson A, Tuck AB, Chambers A, Rodenhiser DI (2010). PLoS ONE 5(1): e8665.
Ischemia dysregulates DNA methyltransferases and p16INK4a methylation in human colorectal cancer cells. Skowronski K, Dubey S, Rodenhiser DI, Coomber BL (2010). Epigenetics 5(6):547-566.
Epigenetic contributions to cancer metastasis. Rodenhiser DI (2009). Clinical and Experimental Metastasis 26 (1): 5-18.
Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF (2008). Breast Cancer Research 10: R62. DOI: 10.1186/bcr2121.
Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene treated MCF7 breast cancer cells. Sadikovic B, Andrews J, Carter D, Robinson J and Rodenhiser DI (2008). J Biological Chemistry 283 (7):4051-4060.
DNA methylation analysis using CpG microarrays is impaired in benzopyrene exposed cells. Sadikovic B, Andrews J and Rodenhiser DI (2007). Toxicology and Applied Pharmacology 225:300-309.
Contact
Phone: 519-685-8600 x 52198
Fax: 519.685.8616
Email: drodenhi [at] uwo [dot] ca
Website: http://publish.uwo.ca/~drodenhi/
(Please note: CHRI is not responsible for the content of any external sites - links will open in new window)
